Skip to Content

Join the 'Atezolizumab' group to help and get support from people like you.

Atezolizumab News

FDA Medwatch Alert: Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Posted 2 days 20 hours ago by Drugs.com

ISSUE: FDA is alerting health care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as single therapy (monotherapy) in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Breast Cancer 'Immunotherapy' Helps Some With Tough-to-Treat Disease

Posted 3 Apr 2017 by Drugs.com

MONDAY, April 3, 2017 – Women with a particularly aggressive form of breast cancer who responded to an new immune-focused drug gained a significant survival benefit, a new study shows. The patients all had what's known as advanced, "triple-negative" breast cancers. "Triple-negative breast cancer is an aggressive subtype of breast cancer often affecting younger women and, unfortunately, the ...

Immune-Focused Drug Shows Promise Against Lung Cancer

Posted 13 Dec 2016 by Drugs.com

TUESDAY, Dec. 13, 2016 – An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study. The findings are from an early analysis of 850 patients with non-small cell lung cancer in a phase 3 trial funded by the drug's makers. According to the American Cancer ...

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two ...

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Posted 19 Oct 2016 by Drugs.com

South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on ...

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of ...

Immune-Based Drug May Help Some With Advanced Bladder Cancer

Posted 5 Jun 2016 by Drugs.com

SUNDAY, June 5, 2016 – Patients with advanced bladder cancer can sometimes be too old or unhealthy to withstand standard chemotherapy. However, some may gain hope from a new drug that unleashes the immune system to attack tumor cells, researchers reported Sunday. Patients who responded to the drug Tecentriq (atezolizumab) had an average survival of nearly 15 months, about 5 to 6 months longer ...

FDA Approves New Drug to Treat Bladder Cancer

Posted 31 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – A new drug to treat bladder cancer was approved by the U.S. Food and Drug Administration on Wednesday. Tecentriq (atezolizumab) treats the most common type of bladder cancer, called urothelial carcinoma. It's the first in its class of drugs, called PD-1/PD-L1 inhibitors, approved to treat this type of cancer. "Tecentriq provides these patients with a new therapy ...

FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma

Posted 18 May 2016 by Drugs.com

May 18, 2016 – The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer. "Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway," said Richard Pazdur, M.D., director of ...

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Bladder Cancer, Urothelial Carcinoma

Related Drug Support Groups

Tecentriq

Atezolizumab Patient Information at Drugs.com